Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis

J Clin Endocrinol Metab. 2006 Dec;91(12):5076-82. doi: 10.1210/jc.2006-1075. Epub 2006 Sep 12.

Abstract

Objective: The objective of this study was to assess whether low-grade systemic inflammation might contribute to the pathogenesis of endothelial dysfunction in patients with subclinical hypothyroidism (sHT) and autoimmune thyroiditis.

Background: sHT patients are characterized by peripheral endothelial dysfunction and low-grade inflammation.

Methods: In 53 sHT and 45 healthy subjects, we studied the forearm blood flow (strain-gauge plethysmography) response to intrabrachial acetylcholine (Ach) (0.15-15 microg/min.dl) with and without local vascular COX inhibition by intrabrachial indomethacin (50 microg/min.dl) or nitric oxide synthase blockade by N-mono methyl arginine (L-NMMA) (100 microg/min.dl) or the antioxidant vitamin C (8 mg/min.dl). The protocol was repeated 2 h after systemic nonselective COX inhibition (100 mg indomethacin) or selective COX-2 blockade (200 mg celecoxib) oral administrations.

Results: sHT patients showed higher C-reactive protein and IL-6 values. In controls, vasodilation to Ach was blunted by L-NMMA and unchanged by vitamin C. In contrast, in sHT, the response to Ach, reduced in comparison with controls, was resistant to L-NMMA and normalized by vitamin C. In these patients, systemic but not local indomethacin normalized vasodilation to Ach and the inhibition of L-NMMA on Ach. Similar results were obtained with celecoxib. When retested after indomethacin administration, vitamin C no longer succeeded in improving vasodilation to Ach in sHT patients. Response to sodium nitroprusside was unchanged by indomethacin or celecoxib.

Conclusions: In sHT patients, low-grade chronic inflammation causes endothelial dysfunction and impaired nitric oxide availability by a COX-2-dependent pathway leading to increased production of oxidative stress.

Publication types

  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Acetylcholine / pharmacology
  • Adult
  • Algorithms
  • Ascorbic Acid / pharmacology
  • Celecoxib
  • Cyclooxygenase 2
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology*
  • Female
  • Forearm / blood supply
  • Hashimoto Disease / complications*
  • Humans
  • Indomethacin / pharmacology
  • Inflammation / complications*
  • Male
  • Membrane Proteins
  • Middle Aged
  • Nitric Oxide / pharmacology
  • Nitroprusside / pharmacology
  • Oxidative Stress / physiology
  • Pyrazoles / pharmacology
  • Regional Blood Flow / drug effects
  • Sulfonamides / pharmacology
  • Vascular Diseases / etiology*
  • Vasculitis / complications
  • Vasodilation / drug effects
  • Vasodilation / physiology

Substances

  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Nitroprusside
  • Nitric Oxide
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Celecoxib
  • Acetylcholine
  • Ascorbic Acid
  • Indomethacin